Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirtris reports positive findings for diabetic drug
In addition, in an intraperitoneal glucose tolerance test, Sirtris’s SIRT1 activator was shown to control glucose excursion as well as sitagliptin in this pre-clinical model of Type 2
In addition, in an intraperitoneal glucose tolerance test, Sirtris’s SIRT1 activator was shown to control glucose excursion as well as sitagliptin in this pre-clinical model of Type 2
Integra has received 510(k) clearance from the FDA to market flowable wound matrix in the US. Tom Tarca, vice president of marketing for the extremity reconstruction business, Integra,
The objective of the study is to determine the safety and tolerability of three doses of ofatumumab and the dose response of ofatumumab on disease activity on MRI
The panel recommended approval of the device contingent upon several conditions, including long-term follow up of current pivotal trial patients, a new post approval study of new patients
The right grants to Becton Dickinson (BD) an exclusive discussion period through March 31, 2008 during which the companies will explore a possible product development relationship and definitive
The study was a randomized, double-blind, placebo-controlled, multi-center, four-week inpatient study that enrolled 604 patients. Following fixed-dose titration, inpatients were randomized to receive iloperidone at 24mg/day, ziprasidone at
Exact Sciences has a portfolio of over 110 issued patents and over 60 pending patent applications in the US, Europe, Japan, Canada, Australia and elsewhere. Jeffrey Luber, president
Neurocrine said that it is now preparing a formal meeting request to the FDA to discuss the 2007 approvable letter. The FDA has notified the company that its
Lazard Freres & Co acted as the lead placement agent with Susquehanna Financial Group and CRT Capital Group acting as co-placement agents in the transaction. Michael Flavin, chairman
The agreement contemplates the merger of a new subsidiary of I-Flow into AcryMed, with AcryMed being the surviving corporation as a wholly owned subsidiary of I-Flow. I-Flow’s obligation